Drug development company NPS Pharmaceuticals, 420 Chipeta Way, had a net loss of $1.6 million or 29 cents per share in the quarter ending June 30 compared with a net loss of $1.8 million or 51 cents per share in the same quarter a year ago.

Hunter Jackson, NPS chief executive officer, said the company had a net loss of $3.3 million or 65 cents per share in the first six months of 1994 compared with a net loss of $3.3 million or 92 cents per share in the same period of 1993."Our product development programs and progress in the clinic continue to require increases in research and development personnel. Our expenses are expected to increase in the future as existing and new product candidates progress toward more advanced stages of clinical development," Jackson said.

Applications of the company's research currently center on hyperparathyroidism, osteoporosis and central nervous system disorders, including chronic pain and brain damage from stroke.

Join the Conversation
Looking for comments?
Find comments in their new home! Click the buttons at the top or within the article to view them — or use the button below for quick access.